Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
University of Sydney · Mater Health Services · +40 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,381
total citations
- FWCI
- 80.71
- Percentile
- 100%
- References
- 15
Citations per year
Authors
34- GVGeorgina V. LongCorresponding
University of Sydney, Mater Health Services, Melanoma Institute Australia
- DSDaniil Stroyakovskiy
Moscow City Oncology Hospital №62
- HGHelen Gogas
National and Kapodistrian University of Athens
- ELE. Levchenko
Institute of Oncology NN Petrov
- FDFilippo de Braud
Fondazione IRCCS Istituto Nazionale dei Tumori
Topics & keywords
Topics
Keywords
- Dabrafenib
- Trametinib
- Medicine
- Clinical endpoint
- Internal medicine
- Hazard ratio
- Melanoma
- Oncology
No related works found for this paper.